

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

Light Treatment and Laser Therapies for Benign Dermatologic Conditions

MP9057

Covered Service: Yes

Prior Authorization Required: No

Additional Information: Prevea360 Health Plan covers the purchase of one system per member per lifetime. The member is responsible for the cost of repairs or replacement lights

Prevea360 Health Plan Medical Policy:

- 1.0 **Phototherapy:** Ultraviolet A and Ultraviolet B (UVA; UVB) **does not** require prior authorization and may be considered medically necessary for **ANY** of the following dermatologic conditions:
 - 1.1 Papulosquamous disorders, such as:
 - 1.1.1 Lichen planus
 - 1.1.2 Pityriasis (e.g. pityriasis rosea; pityriasis rotunda)
 - 1.1.3 Psoriasis
 - 1.2 Superficial mycoses (e.g. dermatophytosis [ringworm])
 - 1.3 Atopic dermatitis (atopic eczema)
 - 1.4 Parapsoriasis
 - 1.5 Repigmentation of the skin in members with vitiligo
- 2.0 **Phototherapies** (UVA and UVB) are considered experimental and investigational and therefore not medically necessary for **ALL** other indications, including but not limited to:
 - 2.1 Acne vulgaris
 - 2.2 Rosacea
 - 2.3 Cholestasis of pregnancy
 - 2.4 Granuloma annular
 - 2.5 Hydradenitis suppurativa
 - 2.6 Lichen simplex chronicus
 - 2.7 Morphea (localized scleroderma)
 - 2.8 Papular urticaria

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

- 2.9 Pruritis scleroderma
- 3.0 **Photochemotherapy** (psoralen plus UV-A [PUVA]) **does not** require prior authorization is considered medically necessary for **ANY** of the following dermatologic conditions:
 - 3.1 Papulosquamous disorders, such as **ANY** of the following:
 - 3.1.1 Lichen planus
 - 3.1.2 Pityriasis (e.g. pityriasis rosea; pityriasis rotunda)
 - 3.1.3 Psoriasis
 - 3.2 Superficial mycoses (e.g. dermatophytosis [ringworm])
 - 3.3 Atopic dermatitis (atopic eczema)
 - 3.4 Parapsoriasis
 - 3.5 Repigmentation of the skin in members with vitiligo
- 4.0 **Photochemotherapy** (PUVA) is considered experimental and investigational, and therefore not medically necessary for all other indications, including but not limited to treatment of acne vulgaris.
- 5.0 **Photodynamic therapy** (PDT) (e.g. light treatment in conjunction with 5-aminolevulinic acid or methyl aminolevulinate) **does not** require prior authorization and is considered medically necessary for the treatment of actinic keratosis (AK), non-hyperkeratotic.
- 6.0 **Photodynamic therapy** (PDT) is considered experimental and investigational and therefore not medically necessary for all other indications, including but not limited to the treatment of acne vulgaris.
- 7.0 **Laser therapy** (excimer laser, pulsed dye laser) **does not** require prior authorization is considered medically necessary for the treatment of **ANY** of the following:
 - 7.1 Localized plaque psoriasis
 - 7.2 Vitiligo
 - 7.3 Atopic dermatitis
 - 7.4 Port wine stain (nevus Flammeus), including Sturge-Weber syndrome
- 8.0 **Laser therapy** is considered experimental and investigational and therefore not medically necessary for **ALL** other indications including but not limited to **ANY** of the following including:
 - 8.1 Non-plaque forms of psoriasis
 - 8.2 Papulosquamous disorders such as:
 - 8.2.1 Lichen planus
 - 8.2.2 Pityriasis rosea
 - 8.3 Superficial mycoses (e.g. dermatophytosis [ringworm])

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

8.4 Acne vulgaris

8.5 Rosacea

8.6 Onychomycosis

8.7 Pilonidal sinus disease

9.0 **Intense pulsed light phototherapy** is considered experimental and investigational and therefore not medically necessary for treatment of all benign dermatological indications, including but not limited to:

9.1 Papulosquamous disorders, including:

9.1.1 Lichen planus

9.1.2 Pityriasis (e.g., pityriasis rosea; pityriasis rotunda)

9.2 Superficial mycoses (e.g., dermatophytosis [ringworm])

9.3 Acne vulgaris

9.4 Atopic dermatitis (atopic eczema)

9.5 Rosacea

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

	Committee/Source	Date(s)
Document		
Created:	UR/Management Committee	November 11, 1987
Revised:	—	
	Utilization Management Committee	November 13, 1991
	Utilization Management Committee/Medical Affairs	January 14, 1998
	Utilization Management Committee/ Medical Affairs/	April 9, 2003
	Utilization Management DME	
	Specialist/Dermatology	March 9, 2005
	Utilization Management Committee/Medical Affairs	March 12, 2008
	Medical Director Committee/Medical Affairs	August 18, 2010
	Medical Policy Committee/Quality and Care	
	Management Division	July 20, 2016
	Medical Policy Committee/Quality and Care	
	Management Division	March 15, 2017
	Medical Policy Committee/Quality and Care	
	Management Division	July 19, 2017
	Medical Policy Committee/Quality and Care	
	Management Division	September 20, 2017
	Medical Policy Committee/Health Services Division	July 17, 2019
	Medical Policy Committee/Health Services Division	July 15, 2020
	Medical Policy Committee/Health Services Division	July 21, 2021
	Medical Policy Committee/Health Services Division	October 19, 2022
	Medical Policy Committee/Health Services Division	April 19, 2023
	Medical Policy Committee/Health Services Division	May 17, 2023
	Medical Policy Committee/Health Services Division	January 17, 2024
Reviewed:	Health Services	October 20, 1997
	Health Services	February 12, 1999
	UMC/CMO/Director Utilization Management	March 13, 2002
	UM Committee (UMC)/Director UM/ UMC Chair	March 12, 2003
	UM Committee (UMC)/Director UM/UMC Chair	March 10, 2004
	UM Committee (UMC)/Director UM/ UMC Chair	March 8, 2006
	Reformatted	March 2006
	Utilization Management Committee/Medical Affairs	April 12, 2006
	UM Committee (UMC)/Director UM/ UMC Chair	March 14, 2007
	UM Committee (UMC)/Director UM/ UMC Chair	March 12, 2008
	UM Committee (UMC)/Director UM/UMC Chair	April 8, 2009
	Medical Director Committee/Medical Affairs	August 18, 2010
	Medical Director Committee/Medical Affairs	August 25, 2011
	Medical Director Committee/Medical Affairs	August 15, 2012
	Medical Director Committee/Medical Affairs	July 17, 2013
	Medical Director Committee/Medical Affairs	July 16, 2014
	Medical Director Committee/Medical Affairs	July 15, 2015

Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

	Committee/Source	Date(s)
Reviewed:	Medical Policy Committee/Quality and Care Management Division	July 20, 2016
	Medical Policy Committee/Quality and Care Management Division	March 15, 2017
	Medical Policy Committee/Quality and Care Management Division	July 19, 2017
	Medical Policy Committee/Quality and Care Management Division	September 20, 2017
	Medical Policy Committee/Health Services Division	July 17, 2019
	Medical Policy Committee/Health Services Division	July 15, 2020
	Medical Policy Committee/Health Services Division	July 21, 2021
	Medical Policy Committee/Health Services Division	October 19, 2022
	Medical Policy Committee/Health Services Division	April 19, 2023
	Medical Policy Committee/Health Services Division	May 17, 2023
	Medical Policy Committee/Health Services Division	January 17, 2024

Published: 02/01/2024

Effective: 02/01/2024